The Emergent Landscape of Detecting EGFR Mutations Using Circulating Tumor DNA in Lung Cancer

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Huang, Wei Lun ^a,b   Wei, Fang ^c   Wong, David T ^c   Lin, Chien Chung ^a   Su, Wu Chou ^a  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c UCLA SCHOOL OF DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCULATING TUMOR DNA; DNA; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR;

ALLELE SPECIFIC POLYMERASE CHAIN REACTION; ARTICLE; BEAMING; BIOASSAY; BODY FLUID; CANCER DIAGNOSIS; CANCER RESISTANCE; CELLULAR SECRETION; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DRUG MONITORING; EARLY DIAGNOSIS; EXOSOME; GENE MUTATION; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; LUNG CANCER; MASS SPECTROMETRY; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; ANIMAL; BLOOD; DNA MUTATIONAL ANALYSIS; GENETICS; LUNG TUMOR; MUTATION; PATHOLOGY;

ANIMALS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; HUMANS; LUNG NEOPLASMS; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84942795366     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/340732     Document Type: Article

References (90)

1. R. Siegel, J. Ma, Z. Zou, and A. Jemal, "Cancer statistics, 2014, " CA Cancer Journal for Clinicians, vol. 64, no. 1, pp. 9-29, 2014.
2. "Targeting resistance in lung cancer, " Cancer Discovery, vol. 3, no. 12, article OF9, 2013.
3. T. J. Lynch, D. W. Bell, R. Sordella et al., "Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to Gefitinib, " The New England Journal of Medicine, vol. 350, no. 21, pp. 2129-2139, 2004.
4. L. A. Diaz Jr. and A. Bardelli, "Liquid biopsies: genotyping circulating tumor DNA, " Journal of Clinical Oncology, vol. 32, no. 6, pp. 579-586, 2014.
5. F.-C. Bidard, B. Weigelt, and J. S. Reis-Filho, "Going with the flow: from circulating tumor cells to DNA, " Science Translational Medicine, vol. 5, no. 207, p. 207ps14, 2013.
6. M. S. Wicha and D. F. Hayes, "Circulating tumor cells: not all detected cells are bad and not all bad cells are detected, " Journal of Clinical Oncology, vol. 29, no. 12, pp. 1508-1511, 2011.
7. P. Mandel and P. Metais, "Les acides nucleiques du plasma sanguin chez l'homme, " Comptes Rendus des Séances de la Société de Biologie et de ses Filiales, vol. 142, no. 3-4, pp. 241-243, 1948.
8. S. A. Leon, B. Shapiro, D. M. Sklaroff, and M. J. Yaros, "Free DNA in the serum of cancer patients and the effect of therapy, " Cancer Research, vol. 37, no. 3, pp. 646-650, 1977.
9. H. Schwarzenbach, D. S. B. Hoon, and K. Pantel, "Cell-free nucleic acids as biomarkers in cancer patients, " Nature Reviews Cancer, vol. 11, no. 6, pp. 426-437, 2011.
10. M. Stroun, J. Lyautey, C. Lederrey, A.Olson-Sand, and P. Anker, "About the possible origin andmechanism of circulatingDNA: apoptosis and active DNA release, " Clinica Chimica Acta, vol. 313, no. 1-2, pp. 139-142, 2001.
11. G. Raposo andW. Stoorvogel, "Extracellular vesicles: exosomes, microvesicles, and friends, " The Journal of Cell Biology, vol. 200, no. 4, pp. 373-383, 2013.
12. M. Guescini, D. Guidolin, L. Vallorani et al., "C2C12 myoblasts release micro-vesicles containing mtDNA and proteins involved in signal transduction, " Experimental Cell Research, vol. 316, no. 12, pp. 1977-1984, 2010.
13. C. Kahlert, S. A. Melo, A. Protopopov et al., "Identification of double-stranded genomic dna spanning all chromosomes with mutated KRAS and P53DNAin the serum exosomes of patients with pancreatic cancer, " The Journal of Biological Chemistry, vol. 289, no. 7, pp. 3869-3875, 2014.
14. B. K. Thakur, H. Zhang, A. Becker et al., "Double-stranded DNA in exosomes: a novel biomarker in cancer detection, " Cell Research, vol. 24, no. 6, pp. 766-769, 2014.
15. D. D. Taylor and C. Gercel-Taylor, "MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer, " Gynecologic Oncology, vol. 110, no. 1, pp. 13-21, 2008.
16. D. Duijvesz, T. Luider, C. H. Bangma, and G. Jenster, "Exosomes as biomarker treasure chests for prostate cancer, " European Urology, vol. 59, no. 5, pp. 823-831, 2011.
17. C. R. Newton, A. Graham, L. E. Heptinstall et al., "Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS), " Nucleic Acids Research, vol. 17, no. 7, pp. 2503-2516, 1989.
18. D. Whitcombe, J.Theaker, S. P. Guy, T. Brown, and S. Little, "Detection of PCR products using self-probing amplicons and fluorescence, " Nature Biotechnology, vol. 17, no. 8, pp. 804-807, 1999.
19. Y. Kuang, A. Rogers, B. Y. Yeap et al., "Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer, " Clinical Cancer Research, vol. 15, no. 8, pp. 2630-2636, 2009.
20. S. Wang, X. Han, X. Hu et al., "Clinical significance of pretreatment plasma biomarkers in advanced non-small cell lung cancer patients, " Clinica Chimica Acta, vol. 430, pp. 63-70, 2014.
21. X. Liu, Y. Lu, G. Zhu et al., "The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies, " Journal of Clinical Pathology, vol. 66, no. 12, pp. 1065-1069, 2013.
22. K. Goto, Y. Ichinose, Y. Ohe et al., "Epidermal growth factor receptormutation status in circulating freeDNAin serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer, " Journal ofThoracic Oncology, vol. 7, no. 1, pp. 115-121, 2012.
23. H. Kimura, M. Suminoe, K. Kasahara et al., "Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA), " British Journal of Cancer, vol. 97, no. 6, pp. 778-784, 2007.
24. H. Kimura, K. Kasahara, M. Kawaishi et al., "Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patientswith non-smallcell lung cancer, " Clinical Cancer Research, vol. 12, no. 13, pp. 3915-3921, 2006.
25. F. Xu, J. Wu, C. Xue et al., "Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib, "OncoTargets andTherapy, vol. 5, pp. 439-447, 2012.
26. G. Pohl and L.-M. Shih, "Principle and applications of digital PCR, " Expert Review of Molecular Diagnostics, vol. 4, no. 1, pp. 41-47, 2004.
27. B. Vogelstein and K. W. Kinzler, "Digital PCR, " Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 16, pp. 9236-9241, 1999.
28. T.K. F. Yung, K. C. A. Chan, T. S.K.Mok, J. Tong, K.-F. To, and Y. M. D. Lo, "Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients, " Clinical Cancer Research, vol. 15, no. 6, pp. 2076-2084, 2009.
29. S. M. Kahn, W. Jiang, T. A. Culbertson, I. B. Weinstein, G. M. Williams, and N. Z. Tomita Ronai, "Rapid and sensitive nonradioactive detection of mutant K-ras genes via 'enriched' PCR amplification, " Oncogene, vol. 6, no. 6, pp. 1079-1083, 1991.
30. H. Asano, S. Toyooka, M. Tokumo et al., "Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay, " Clinical Cancer Research, vol. 12, no. 1, pp. 43-48, 2006.
31. X. Zhao, R.-B. Han, J. Zhao et al., "Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients, " Respiration, vol. 85, no. 2, pp. 119-125, 2013.
32. B. Jiang, F. Liu, L. Yang et al., "Serum detection of epidermal growth factor receptor gene mutations using mutant-enriched sequencing in Chinese patients with advanced non-small cell lung cancer, " Journal of International Medical Research, vol. 39, no. 4, pp. 1392-1401, 2011.
33. C. He, M. Liu, C. Zhou et al., "Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer, " International Journal of Cancer, vol. 125, no. 10, pp. 2393-2399, 2009.
34. A. Ray and B. Nordén, "Peptide nucleic acid (PNA): its medical and biotechnical applications and promise for the future, " The FASEB Journal, vol. 14, no. 9, pp. 1041-1060, 2000.
35. P. Wittung, P. E. Nielsen, O. Buchardt, M. Egholm, and B. Nordén, "DNA-like double helix formed by peptide nucleic acid, " Nature, vol. 368, no. 6471, pp. 561-563, 1994.
36. C.-C. Chiou, J.-D. Luo, and T.-L. Chen, "Single-tube reaction using peptide nucleic acid as both PCR clamp and sensor probe for the detection of rare mutations, " Nature Protocols, vol. 1, no. 6, pp. 2604-2612, 2007.
37. L. A. Ugozzoli, D. Latorra, R. Pucket, K. Arar, and K. Hamby, "Real-time genotyping with oligonucleotide probes containing locked nucleic acids, " Analytical Biochemistry, vol. 324, no. 1, pp. 143-152, 2004.
38. J. Obradovic and V. Jurisic, "Evaluation of current methods to detect the mutations of epidermal growth factor receptor in non-small cell lung cancer patients, " Multidisciplinary Respiratory Medicine, vol. 7, no. 7, article 52, 2012.
39. Y. Nagai, H. Miyazawa, T. Tanaka et al., "Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp, " Cancer Research, vol. 65, no. 16, pp. 7276-7282, 2005.
40. T. Tanaka, Y. Nagai, H. Miyazawa et al., "Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers, " Cancer Science, vol. 98, no. 2, pp. 246-252, 2007.
41. A. Sutani, Y. Nagai, K. Udagawa et al., "Gefitinib for non-smallcell lung cancer patients with epidermal growth factor receptor genemutations screened by peptide nucleic acid-locked nucleic acid PCR clamp, " British Journal of Cancer, vol. 95, no. 11, pp. 1483-1489, 2006.
42. H.-R. Kim, S. Y. Lee, D.-S. Hyun et al., "Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping, " Journal of Experimental & Clinical Cancer Research, vol. 32, no. 1, article 50, 2013.
43. S. T. Kim, J. S. Sung, U. H. Jo, K. H. Park, S. W. Shin, and Y. H. Kim, "Canmutations of EGFRandKRASin serumbe predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)?" Medical Oncology, vol. 30, no. 1, article 328, 2013.
44. D.Dressman, H. Yan, G. Traverso, K.W. Kinzler, and B. Vogelstein, "Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations, " Proceedings of the National Academy of Sciences of theUnited States ofAmerica, vol. 100, no. 15, pp.8817-8822, 2003.
45. F. Diehl, K. Schmidt, K. H. Durkee et al., "Analysis ofmutations in DNA isolated from plasma and stool of colorectal cancer patients, " Gastroenterology, vol. 135, no. 2, pp. 489.e7-498.e7, 2008.
46. J. Lauring and B. H. Park, "BEAMing sheds light on drug resistance, " Clinical Cancer Research, vol. 17, no. 24, pp. 7508-7510, 2011.
47. A. L. Richardson and J. D. Iglehart, "BEAMing up personalized medicine: mutation detection in blood, " Clinical Cancer Research, vol. 18, no. 12, pp. 3209-3211, 2012.
48. K. Taniguchi, J. Uchida, K. Nishino et al., "Quantitative detection of EGFRmutations in circulating tumorDNAderived from lung adenocarcinomas, " Clinical Cancer Research, vol. 17, no. 24, pp. 7808-7815, 2011.
49. C. Ding, R. W. K. Chiu, T. K. Lau et al., "MS analysis of singlenucleotide differences in circulating nucleic acids: application to noninvasive prenatal diagnosis, " Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 29, pp. 10762-10767, 2004.
50. K. Sakai, A. Horiike, D. L. Irwin et al., "Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor, " Cancer Science, vol. 104, no. 9, pp. 1198-1204, 2013.
51. M. Brevet, M. L. Johnson, C. G. Azzoli, and M. Ladanyi, "Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors, " Lung Cancer, vol. 73, no. 1, pp. 96-102, 2011.
52. C. Hu, X. Liu, Y. Chen et al., "Direct serum and tissue assay for EGFR mutation in non-small cell lung cancer by highresolutionmelting analysis, " Oncology Reports, vol. 28, no. 5, pp. 1815-1821, 2012.
53. C. F. Taylor, "Mutation scanning using high-resolutionmelting, " Biochemical Society Transactions, vol. 37, no. 2, pp. 433-437, 2009.
54. G. Keller, A. Hartmann, J. Mueller, and H. Höfler, "Denaturing high pressure liquid chromatography (DHPLC) for the analysis of somatic p53 mutations, " Laboratory Investigation, vol. 81, no. 12, pp. 1735-1737, 2001.
55. P. A. Jänne, A.M. Borras, Y. Kuang et al., "A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening, " Clinical Cancer Research, vol. 12, no. 3, pp. 751-758, 2006.
56. V. Cohen, J. S. Agulnik, J. Jarry et al., "Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer, " Cancer, vol. 107, no. 12, pp. 2858-2865, 2006.
57. H. Bai, L. Mao, H. S. Wang et al., "Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-smallcell lung cancer, " Journal of Clinical Oncology, vol. 27, no. 16, pp. 2653-2659, 2009.
58. T. M. Chin, D. Anuar, R. Soo et al., "Detection of epidermal growth factor receptor variations by partially denaturing HPLC, " Clinical Chemistry, vol. 53, no. 1, pp. 62-70, 2007.
59. E. R. Mardis, "Next-generation sequencing platforms, " Annual Review of Analytical Chemistry, vol. 6, pp. 287-303, 2013.
60. M. L. Metzker, "Sequencing technologies the next generation, " Nature Reviews Genetics, vol. 11, no. 1, pp. 31-46, 2010.
61. H. L. Rehm, "Disease-targeted sequencing: a cornerstone in the clinic, " Nature Reviews Genetics, vol. 14, no. 4, pp. 295-300, 2013.
62. J. C. Mwenifumbo and M. A. Marra, "Cancer genomesequencing study design, " Nature Reviews Genetics, vol. 14, no. 5, pp. 321-332, 2013.
63. M. T. Lin, S. L. Mosier, M. Thiess et al., "Clinical validation of KRAS, BRAF, and EGFR mutation detection using nextgeneration sequencing, " American Journal of Clinical Pathology, vol. 141, no. 6, pp. 856-866, 2014.
64. D. de Biase, M. Visani, U. Malapelle et al., "Next-generation sequencing of lung cancer EGFR exons 18-21 allows effective molecular diagnosis of small routine samples (cytology and biopsy), " PLoS ONE, vol. 8, no. 12, Article IDe83607, 2013.
65. H. S. Kim, J. S. Sung, S.-J. Yang et al., "Predictive efficacy of low burden EGFR mutation detected by next-generation sequencing on response to EGFR tyrosine kinase inhibitors in non-small-cell lung carcinoma, " PLoSONE, vol. 8, no. 12, Article ID e81975, 2013.
66. Y. Kukita, J. Uchida, S. Oba et al., "Quantitative identification of mutant alleles derived from lung cancer in plasma cell-free DNA via anomaly detection using deep sequencing data, " PLoS ONE, vol. 8, no. 11, Article ID e81468, 2013.
67. S. Couraud, F. Vaca-Paniagua, S. Villar et al., "Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proofof-concept study from BioCAST/IFCT-1002, " Clinical Cancer Research, vol. 20, no. 17, pp. 4613-4624, 2014.
68. V. Casadio, D. Calistri, S. Salvi et al., "Urine cell-free DNA integrity as a marker for early prostate cancer diagnosis: a pilot study, " BioMed Research International, vol. 2013, Article ID 270457, 5 pages, 2013.
69. V. Casadio, D. Calistri, M. Tebaldi et al., "Urine cell-free DNA integrity as a marker for early bladder cancer diagnosis: preliminary data, " Urologic Oncology: Seminars and Original Investigations, vol. 31, no. 8, pp. 1744-1750, 2013.
70. S.H. Zhang, S.M. Zhao, Z. M. Zhao, and C. T. Li, "Genotyping of urinary samples stored with EDTA for forensic applications, " Genetics and Molecular Research, vol. 11, no. 3, pp. 3007-3012, 2012.
71. D. M. Hyman, E. L. Diamond, C. R. Vibat et al., "Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders, " Cancer Discovery, vol. 5, no. 1, pp. 64-71, 2015.
72. F. Janku, C. R. T. Vibat, G. S. Falchook et al., "Longitudinal monitoring of BRAF V600Emutation in urinary cell-free DNA of patients with metastatic cancers, " ASCO Annual Meeting, abstract e22175, 2014.
73. K. C. A. Chan, S.-W. Yeung, W.-B. Lui, T. H. Rainer, and Y. M. D. Lo, "Effects of preanalytical factors on the molecular size of cell-free DNA in blood, " Clinical Chemistry, vol. 51, no. 4, pp. 781-784, 2005.
74. P.Denny, F. K.Hagen, M.Hardt et al., "Theproteomes of human parotid and submandibular/sublingual gland salivas collected as the ductal secretions, " Journal of Proteome Research, vol. 7, no. 5, pp. 1994-2006, 2008.
75. N. Spielmann andD.Wong, "Saliva: diagnostics and therapeutic perspectives, " Oral Diseases, vol. 17, no. 4, pp. 345-354, 2011.
76. T. Rylander-Rudqvist, N. Håkansson, G. Tybring, andA.Wolk, "Quality and quantity of saliva DNA obtained from the selfadministrated oragene method - a pilot study on the cohort of Swedish men, " Cancer Epidemiology, Biomarkers & Prevention, vol. 15, no. 9, pp. 1742-1745, 2006.
77. M.-L. Looi, H. Zakaria, J. Osman, and R. Jamal, "Quantity and quality assessment of DNA extracted from saliva and blood, " Clinical Laboratory, vol. 58, no. 3-4, pp. 307-312, 2012.
78. T. V. O. Hansen, M. K. Simonsen, F. C. Nielsen, and Y. A. Hundrup, "Collection of blood, saliva, and buccal cell samples in a pilot study on the Danish nurse cohort: comparison of the response rate and quality of genomic DNA, " Cancer Epidemiology Biomarkers and Prevention, vol. 16, no. 10, pp. 2072-2076, 2007.
79. N. J. Bonne and D. T. W. Wong, "Salivary biomarker development using genomic, proteomic and metabolomic approaches, " Genome Medicine, vol. 4, no. 10, article 82, 2012.
80. F. Wei, C. Lin, A. Joon et al., "Noninvasive saliva-based EGFR gene mutation detection in patients with lung cancer, " The American Journal of Respiratory and Critical CareMedicine, vol. 190, no. 10, pp. 1117-1126, 2014.
81. J. Luo, L. Shen, and D. Zheng, "Diagnostic value of circulating free DNA for the detection of EGFRmutation status in NSCLC: a systematic review and meta-analysis, " Scientific Reports, vol. 4, article 6269, 2014.
82. S. Kobayashi, T. J. Boggon, T. Dayaram et al., "EGFR mutation and resistance of non-small-cell lung cancer to gefitinib, " The New England Journal of Medicine, vol. 352, no. 8, pp. 786-792, 2005.
83. W. Pao, V. A.Miller, K. A. Politi et al., "Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associatedwith a secondmutation in the EGFR kinase domain, " PLoSMedicine, vol. 2, no. 3, article e73, 2005.
84. R. K. Thomas, H. Greulich, Y. Yuza et al., "Detection of oncogenicmutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors, " Cold Spring Harbor Symposia on Quantitative Biology, vol. 70, pp. 73-81, 2005.
85. K. Taniguchi, J. Uchida, K. Nishino et al., "Quantitative detection of EGFRmutations in circulating tumorDNAderived from lung adenocarcinomas, " Clinical Cancer Research, vol. 17, no. 24, pp. 7808-7815, 2011.
86. D. R. Aberle, A. M. Adams, C. D. Berg et al., "Reduced lung-cancer mortality with low-dose computed tomographic screening, " The New England Journal of Medicine, vol. 365, no. 5, pp. 395-409, 2011.
87. K. Courtright and S. Manaker, "Counterpoint: should lung cancer screening by chest CT scan be a covered benefit? No, " Chest, vol. 147, no. 2, pp. 289-292, 2015.
88. A. M. Newman, S. V. Bratman, J. To et al., "An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage, " Nature Medicine, vol. 20, no. 5, pp. 548-554, 2014.
89. X. Zhang, Y. L.Wu, J. Wang et al., "A prospective comparison study on EGFR mutations by direct sequencing and ARMS in completely resected Chinese non-small cell lung cancer with adenocarcinoma histology (ICAN), " in Proceedings of the ASCO Annual Meeting, European Society forMedical Oncology, 2014.
90. Y. Shi, J. S.-K. Au, S.Thongprasert et al., "A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER), " Journal of ThoracicOncology, vol. 9, no. 2, pp. 154-162, 2014.